X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs DIVIS LABORATORIES - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD DIVIS LABORATORIES ORCHID PHARMA LTD/
DIVIS LABORATORIES
 
P/E (TTM) x -0.1 35.9 - View Chart
P/BV x 0.1 7.0 1.8% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ORCHID PHARMA LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
DIVIS LABORATORIES
Mar-18
ORCHID PHARMA LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1941,142 17.0%   
Low Rs35533 6.6%   
Sales per share (Unadj.) Rs276.5146.6 188.6%  
Earnings per share (Unadj.) Rs-79.233.0 -239.8%  
Cash flow per share (Unadj.) Rs-43.538.4 -113.1%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs53.9222.8 24.2%  
Shares outstanding (eoy) m70.45265.47 26.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.45.7 7.2%   
Avg P/E ratio x-1.425.3 -5.7%  
P/CF ratio (eoy) x-2.621.8 -12.1%  
Price / Book Value ratio x2.13.8 56.5%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m8,067222,318 3.6%   
No. of employees `0002.810.8 26.0%   
Total wages/salary Rs m2,5274,561 55.4%   
Avg. sales/employee Rs Th6,956.13,616.0 192.4%   
Avg. wages/employee Rs Th902.5423.8 213.0%   
Avg. net profit/employee Rs Th-1,993.0814.9 -244.6%   
INCOME DATA
Net Sales Rs m19,47738,915 50.1%  
Other income Rs m4071,134 35.9%   
Total revenues Rs m19,88440,049 49.6%   
Gross profit Rs m1,10312,617 8.7%  
Depreciation Rs m2,5191,425 176.8%   
Interest Rs m5,22713 39,299.2%   
Profit before tax Rs m-6,23612,313 -50.6%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1253,543 -3.5%   
Profit after tax Rs m-5,5808,770 -63.6%  
Gross profit margin %5.732.4 17.5%  
Effective tax rate %2.028.8 7.0%   
Net profit margin %-28.722.5 -127.1%  
BALANCE SHEET DATA
Current assets Rs m11,01445,351 24.3%   
Current liabilities Rs m32,0606,507 492.7%   
Net working cap to sales %-108.199.8 -108.3%  
Current ratio x0.37.0 4.9%  
Inventory Days Days95127 74.9%  
Debtors Days Days3495 35.3%  
Net fixed assets Rs m29,44021,160 139.1%   
Share capital Rs m705531 132.7%   
"Free" reserves Rs m2,04358,625 3.5%   
Net worth Rs m3,80059,156 6.4%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51067,832 68.6%  
Interest coverage x-0.2926.8 -0.0%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.6 73.0%   
Return on assets %-0.812.9 -5.9%  
Return on equity %-146.914.8 -990.6%  
Return on capital %-3.720.8 -17.9%  
Exports to sales %37.90-   
Imports to sales %22.621.8 103.7%   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,4068,485 51.9%   
Fx inflow Rs m7,51332,359 23.2%   
Fx outflow Rs m5,6499,042 62.5%   
Net fx Rs m1,86523,317 8.0%   
CASH FLOW
From Operations Rs m1,6827,759 21.7%  
From Investments Rs m-9,860-4,783 206.2%  
From Financial Activity Rs m6,644-3,142 -211.5%  
Net Cashflow Rs m-1,535-166 924.7%  

Share Holding

Indian Promoters % 32.3 52.0 62.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 11.8 39.0%  
FIIs % 3.3 19.0 17.4%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.2 321.5%  
Shareholders   84,811 31,796 266.7%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  PLETHICO PHARMA  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Nov 16, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS